Most small-size observational studies or case series consistently found that CytoSorb treatment was effective in alleviating inflammation [IL-6, procalcitonin, CRP, ferritin] (85–89), decreasing D-dimer (86), and improving oxygenation and hemodynamics (88–90) in critically ill COVID-19 patients with refractory ARDS or MODS. The gene discussed is IL6; the disease is acute respiratory distress syndrome.